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Background: Meningeal carcinomatosis (MC) is a rare complication associated with hematologic and solid tumors.
MC develops when malignant cells gain access to the leptomeningeal space, producing several clinical symptoms.
Loss of vision and ocular motility deficit are the most frequent ocular symptoms reported. Fundus examination
usually appears normal, although optic nerve alterations like optic atrophy or papilledema have been described. MC
diagnosis is usually completed by magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analysis.
Indicated treatment for MC usually involves intrathecal chemotherapy combined with radiotherapy, although
survival rate is extremely low.
Case presentation: A 66-year old man with stage IV metastatic lung adenocarcinoma, presented to the
Ophthalmology Department with a two-month history of double vision, soft headaches and dizziness episodes. The
patient presented a best visual corrected acuity of 0.7 in his right eye and 0.8 in his left eye. Diplopia was corrected
with 6-prism diopters base-out prism in right eye. Funduscopy showed a bilateral papilledema, juxtapapillary
exudates and splinter hemorrhages. Brain MRI showed a diffuse leptomeningeal enhancement in cortical sulcus.
Lumbar puncture was performed and cerebrospinal fluid (CSF) cytology revealed malignant cells compatible with a
diagnosis of MC. Intrathecal chemotherapy was administered.
Conclusion: MC is a serious complication of systemic cancer patients, involving a poor prognosis. Early diagnosis is
extremely important, although treatment is frequently aimed to reduce the symptoms and extend survival. Eye
symptoms may be the chief complaint, so MC should be considered in any patient with vision loss or diplopia
accompanied by neurologic symptoms and in the absence of an intraocular cause, especially in the context of
systemic cancer.Background
Meningeal carcinomatosis (MC) is a rare and severe
complication of a number of neoplastic processes.
Hematologic tumors are the most frequent cause of MC,
particularly acute lymphoblastic leukemia and non-
Hodking lymphoma. Among solid tumors, the most fre-
quent causes of MC are breast and lung adenocarcinoma
as well as melanoma. The incidence of this complication
is around 3% in breast cancer, 7% in lung cancer and
1.5% in melanoma [1]. MC is the first manifestation of
systemic cancer in only 5-10% of patients, although it is* Correspondence: lmsadaba@unav.es
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reproduction in any medium, provided the orfrequently seen in patients with disseminated systemic
disease [2,3].
MC occurs when tumor cells reach the leptomeningeal
space either through the blood, the cerebrospinal fluid
(CSF) or by growing along nerve and vascular sheaths.
As a consequence, most patients present with different
multifocal neurological symptoms that may involve the
cranial nerves (oculomotor, facial, cochlear and optic),
the spine and the cerebrum [3,4]. Ocular symptoms were
first reported by Katz, being diplopia and vision loss the
most frequent ocular complaints [1,5].
Early diagnosis and treatment are usually very compli-
cated. Magnetic resonance imaging (MRI) is more sensi-
tive than computed tomography (CT) scan in detecting
brain meningeal dissemination, although the spineLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Sabater et al. BMC Ophthalmology 2012, 12:65 Page 2 of 4
http://www.biomedcentral.com/1471-2415/12/65should also be assessed by MRI or CT myelography [6].
MRI may show focal or diffuse leptomeningeal enhance-
ment as well as tumoral lesions [7]. However, these find-
ings are non-specific, and should be evaluated in the
particular clinical context. On the other hand, CSF ana-
lysis should be performed in all patients with suspected
MC. Malignant cells are detected in the CSF in only 50%
of patients with MC in the first lumbar puncture [8].
Therefore, repeated CSF sampling is usually needed. Fi-
nally, the CSF protein concentration (50 mg/dl) and the
opening CSF pressure (>25 cm H2O) are frequently ele-
vated, whereas the glucose concentration (<60 mg/dl) is
usually decreased.
Differential diagnosis should include inflammatory
processes (rheumatoid arthritis, eosinophilic granuloma),
infections, granulomatous infiltrations (sarcoid, tubercu-
lar), previous administration of chemotherapy, venous
thrombosis, subarachnoid haemorrhage, trauma and
previous intracranial surgeries [9].
MC is associated with a bad prognosis with a mean
survival rate of 3–6 months [10]. Treatment aims to ex-
tend survival and stabilize or improve neurological
symptoms [3]. Surgical treatment includes the placement
of a ventriculoperitoneal shunt in patients with symp-
tomatic hydrocephalus, although these patients have
very poor prognosis [11,12]. Involved-field radiotherapy
may also be applied to patients with MC, although it
does not commonly achieve a prolonged survival [13].
On the other hand, intrathecal or ventricular adminis-
tered chemotherapy is a more selective and less toxic
treatment for patients with MC [8]. Methotrexate, cyto-
sine arabinoside and thiotepa are the most frequent
drugs, although other substances have been tested in
several clinical trials [1].
Case presentation
A 66-year old white man with a history of benign pros-
tatic hyperplasia and tuberculosis, presented to the Oph-
thalmology Department complaining of double vision,
non-intense headaches and dizziness episodes from twoFigure 1 Funduscopic examination. A: Right eye. B: Left eye. Funduscop
exudates and splinter hemorrhages. The macula and blood vessels showedmonths ago. The patient was diagnosed fours month ago
of stage IV lung adenocarcinoma with pericardial and
bone metastases, in treatment with Alimta plus Carbo-
platin and Zoledronic Acid. Brain MRI performed four
days ago showed no brain lesions.
In the ophthalmologic exploration the patient pre-
sented a best visual corrected acuity of 0.7 and 0.8 in
right and left eye respectively, with diplopia corrected
with 6-prism diopters base-out prism in right eye. Fun-
duscopy showed a bilateral papilledema with juxtapapil-
lary exudates and splinter hemorrhages (Figure 1),
suggesting intracranial hypertension. The macula and
blood vessels showed no alterations.
The patient was admitted for further evaluation. One
week later the patient suffered two consecutive auto-
limited partial motor crises. CT scan showed no intra-
cranial hemorrhages or orbital lesions. In contrast, brain
MRI showed a diffuse leptomeningeal enhancement in
cortical sulcus, especially in frontal, temporal and par-
ietal lobes (Figure 2). Lumbar puncture was performed
and CSF was analyzed showing aggregates of atypical
epithelial cells, lymphocytes, cell detritus and red blood
cells. CSF flow analysis revealed a pressure of 40 cm
H2O, a protein concentration of 68.30 mg/dl and a glu-
cose concentration of 35 mg/dl. Based on clinical symp-
toms and according to the test results, the patient was
diagnosed of MC. Next day, a 15 mg dose of intrathecal
methotrexate was administered. Methotrexate was fur-
ther administered on a weekly basis. Five weeks later,
CSF was analyzed and tumor cytology was negative.
Consequently, Methotrexate was administered every
three weeks. Finally, after 1.5 months of treatment, the
patient referred diplopia stabilization.
Conclusion
MC is becoming a relatively frequent complication sec-
ondary to systemic cancer patients, as a consequence of
better survival rates [8]. MC occurs when tumor cells
disseminate and grow in the leptomeningeal space and/
or the cerebrospinal fluid (CSF). Consequently, theseic examination revealed bilateral papilledema with juxtapapillary
no alterations.
Figure 2 Brain Magnetic Resonance Imaging. Axial T2-FLAIR brain
MRI scan shows leptomeningeal enhancement in right parietal
cortex.
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logical symptoms. As demonstrated in this case, our pa-
tient complained of double vision as well as headaches
and dizziness episodes. Furthermore, funduscopy
revealed an evident bilateral papilledema that in associ-
ation with a metastatic lung adenocarcinoma clearly
orientated the diagnosis towards a neurologic process. In
these cases, early diagnosis is important, although treat-
ment is intended to reduce the symptoms and at best
extend survival, especially when neurologic symptoms
are already present [14].
Currently, diagnostic approach to ascertain MC
requires performing cranial and spinal MRI, CSF cy-
tology, CSF flow analysis and CSF glucose and protein
concentration [15]. In first place, a CT scan was per-
formed and it showed no brain lesions. In contrast, brain
MRI, which is more sensitive that CT for detecting brain
meningeal dissemination, showed a diffuse leptomenin-
geal enhancement, which was compatible with the diag-
nosis of MC. On the other hand, spinal MRI was
completely normal. In second place, CSF cytology
showed several malignant aggregated cells in the sample.
However, in some other cases where there is a clinically
suspected MC and negative CSF cytology, different
tumour-specific markers may be evaluated [11]. Finally,
CSF flow analysis revealed an elevated intracranial pres-
sure, a high protein concentration and a low glucose
concentration. Accordingly, diagnosis of MC was made
based on the clinical symptoms and the test results.
The patient received treatment for MC with intra-
thecal methotrexate, which was further administered on
a weekly basis until CSF cytology became negative afterfive weeks. Then, treatment was administered every
three weeks. Although systemic chemotherapy at high
doses could be useful in this case, intrathecal chemo-
therapy allows a better distribution throughout the sub-
arachnoid space with less systemic toxicity [1]. After 1.5
months of treatment, the patient referred stabilization of
the neurological symptoms, including diplopia. Intra-
thecal methotrexate acts by inhibiting the metabolism of
folic acid. Therefore, inhibits the synthesis of DNA,
RNA, thymidylates, and proteins, having a greater toxic
effect on rapidly dividing cells. Thus, methotrexate was
effective in this case by reducing the uncontrolled local
growth of tumoral cells that were responsible for diplo-
pia and other neurological symptoms.
In conclusion, ocular symptom(s) may be the chief
complaint of MC. For that reason, leptomeningeal car-
cinomatosis should be considered in any patient with
ocular symptoms in the absence of an intraocular cause,
particularly in the setting of disseminated cancer.Consent
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